IGFBP5 antisense and short hairpin RNA (shRNA) constructs improve erectile function by inducing cavernosum angiogenesis in diabetic mice
Open Access
Abstract
Background: The incidence of diabetic erectile dysfunction (ED) is rapidly increasing, and due to the severe angiopathy caused by diabetes, current drugs are ineffective at treating ED. Insulin‐like growth factor‐binding protein 5 (IGFBP5) promotes cell death and induces apoptosis in various cell types.Objectives: To evaluate the effectiveness of IGFBP5 knockdown in improving erectile function in diabetic mice.Materials and methods: Diabetes was induced by injecting streptozotocin (STZ) intraperitoneally into male 8‐week‐old C57BL/6 mice. Eight weeks after diabetes induction, mice were divided into four groups: a nondiabetic control group and three STZ‐induced diabetic mice groups, which were administered intracavernous injections of phosphate buffered saline, scrambled control shRNA, or shRNA targeting mouse IGFBP5 (shIGFBP5) lentivirus particles. Two weeks later, we measured erectile function by electrically stimulating the bilateral cavernous nerve. To mimic diabetic angiopathy, primary cavernous endothelial cells (MCECs) from healthy mice were cultured and treated with glucose.Results: IGFBP5 expression in MCECs or cavernous tissues were significantly increased under diabetic conditions, and knockdown of IGFBP5 induced MCECs angiogenic activity under high‐glucose conditions. STZ‐induced diabetic mice had reduced erectile function, but shIGFBP5 treatment resulted in significant improvements (to 90% of the nondiabetic control group level). Furthermore, in diabetic mice, numbers of cavernous endothelial cells, pericytes, and neuronal cells were increased by shIGFBP5 treatment, which also increased eNOS Ser1177 phosphorylation, decreased permeability and apoptosis of cavernous endothelial cells. In addition, IGFBP5 was found to mediate the AKT, ERK, p38 signaling pathways.Discussion and conclusion: Knockdown of IGFBP5 improved erectile function in diabetic mice by promoting cell proliferation and reducing apoptosis and permeability. Local inhibition of IGFBP5 expression may provide a new treatment strategy for diabetic ED and other ischemic vascular or neurological diseases.Keywords
Funding Information
- National Research Foundation of Korea (2021R1A2C4002133)
This publication has 38 references indexed in Scilit:
- Matrigel-Based Sprouting Endothelial Cell Culture System from Mouse Corpus Cavernosum is Potentially Useful for the Study of Endothelial and Erectile Dysfunction Related to High-Glucose ExposureThe Journal of Sexual Medicine, 2012
- Endothelial Dysfunction, Inflammation, and Apoptosis in Diabetes MellitusMediators of Inflammation, 2010
- Diabetes Exacerbates the Functional Deficiency of NO/cGMP Pathway Associated with Erectile Dysfunction in Human Corpus Cavernosum and Penile ArteriesThe Journal of Sexual Medicine, 2010
- Functional and Morphologic Characterizations of the Diabetic Mouse Corpus Cavernosum: Comparison of a Multiple Low-Dose and a Single High-Dose Streptozotocin ProtocolsThe Journal of Sexual Medicine, 2009
- Aortic Ring AssayJournal of Visualized Experiments, 2009
- Erectile Dysfunction in Diabetes MellitusThe Journal of Sexual Medicine, 2009
- Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functionsJournal of Neuroscience Research, 2009
- Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesisCarcinogenesis, 2008
- Insulin-Like Growth Factor-1 Restores Erectile Function in Aged Rats: Modulation the Integrity of Smooth Muscle and Nitric Oxide-Cyclic Guanosine Monophosphate Signaling ActivityThe Journal of Sexual Medicine, 2008
- Optimisation of PDE5 Inhibitor Therapy in Men with Erectile Dysfunction: Converting “Non-Responders” into “Responders”European Urology, 2006